'813 Continues To Regulate Glycemia & Evade Immunity In Mice; Q4 IND On Track

Research evidence excerpt

'813 Continues To Regulate Glycemia & Evade Immunity In Mice; Q4 IND On Track

TD Cowen Century Therapeutics

Global Research June 8, 2026

CNTY-813 Regulates Glycemia In Humanized T1D Mouse Model Engrafted With

Human PBMCs

Source: Century Therapeutics

Century has established its manufacturing processes for Phase 1. Data presented

demonstrated consistent product quality across three separate experiments from Century’s

GMP Master Cell Bank, comprising 11 samples, with optimal endocrine purity, islet cell content,

and minimal islet cell impurities.

Phase I Manufacturing Process Produces Consistent Final Product

We are encouraged that '813's development is on track and view the updates as supportive

of CNTY-813's potential to overcome the historical limitations of cell therapy in T1D including

prohibitive manufacturing costs and the need for chronic immunosuppression. With 2.1MM

people with T1D in the U.S. and treatment options beyond exogenous insulin limited, we

think '813 addresses a large and potentially lucrative market that would embrace a curative

therapy. As CNTY-813's IND is on track for Q4:26, we look forward to initial Ph1 data in H2:27 to

further define '813's profile.

The News: In ADA Dataset, CNTY-813, Allogenic Cell Therapy For T1D,

Regulates Glycemia and Evades Immunity In Multiple Mouse Models of T1D

Century's lead asset is CNTY-813, an allogenic, iPSC-derived, beta islet cell therapy for the

treatment of T1D. '813 leverages the company's proprietary Allo-Evasion 5.0 platform, a

collection of genetic edits (HLA-I/II KOs, CD300a TASR insertion, and IgG degrading enzyme

insertion) that confer T cell, NK cell, and humoral immunity evasion, to enable sustained

engraftment potentially without the need of chronic immunosuppression.

2 TDSecurities.com